PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29091313-0	2018	Exenatide upregulates gene expression of glucagon-like peptide-1 receptor and nerve growth factor in streptozotocin/nicotinamide-induced diabetic mice.	Exenatide	0-9	glucagon-like peptide 1 receptor	Mus musculus	41-73	
29091313-7	2018	Exenatide, a potent and selective agonist for the GLP-1 receptor, is currently approved for the treatment of type 2 diabetes mellitus.	Exenatide	0-9	glucagon-like peptide 1 receptor	Mus musculus	50-64	
29091313-8	2018	The aim of this study was to assess the effect of chronic exenatide treatment on the hippocampal gene expression levels of GLP-1 receptor and NGF in diabetic mice.	Exenatide	58-67	glucagon-like peptide 1 receptor	Mus musculus	123-137	
29091313-9	2018	The effects of chronic exenatide treatment (0.1 mug/kg, s.c., twice daily for 2 weeks) on GLP-1 receptor and NGF gene expression levels in the hippocampus of streptozotocin/nicotinamide (STZ-NA)-induced diabetic mice were assessed by quantitative real-time polymerase chain reaction (RT-PCR).	Exenatide	23-32	glucagon-like peptide 1 receptor	Mus musculus	90-104	
29091313-11	2018	Importantly, a significant increase in the gene expression level of GLP-1 receptor and NGF was determined after 2 weeks of exenatide administration.	Exenatide	123-132	glucagon-like peptide 1 receptor	Mus musculus	68-82	
29091313-12	2018	Increased gene expression level of GLP-1 receptor and NGF may underlie the beneficial action of exenatide in STZ/NA-induced diabetes.	Exenatide	96-105	glucagon-like peptide 1 receptor	Mus musculus	35-49